Ginkgo Bioworks Holdings DNA

$9.99 +0.28 (2.88%)

Valuation

Market cap
672,727,000
Revenue TTM
$170,160,000
Net income TTM
$-312,760,000
PE ratio
0.00
Forward PE
—
Profit margin
-183.80%
Debt to equity
0.00

Trading

Volume
1,156,100
Avg volume
2,343,928
Day's range
$9.43 – $9.99
Shares out
67,340,000
Stochastic %K
19%
Beta
1.79
Analysts
Buy
Price target
$8.00

Price

Company profile

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence mode...

Show more

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
877 422 5362
Website
https://www.ginkgo.bio
Address
27 Drydock Avenue, 8th Floor, Boston, United States

Latest news

Stocktwits

madnessofcrowds Oct 24, 1:00 PM
$DNA still early. folks waking up to the experimental bottleneck.
1 replies
iomete_stulta Oct 23, 8:15 PM
$DNA biotech (finally) added to COINS Act: > The COINS Act directs the Secretary of the Treasury (the Secretary) to issue regulations that (1) require United States persons to provide notification to Treasury regarding certain transactions involving covered foreign persons that are engaged in notifiable technologies, and (2) prohibit United States persons from engaging in certain other transactions involving covered foreign persons that are engaged in prohibited technologies. >the Secretary has added biotechnology to the proposed regulations. https://home.treasury.gov/news/press-releases/sb0667/
0 replies
Bloodmooncapital Oct 23, 5:57 PM
$DNA howlingmadness has been FEASTING on this turkey for years. and has been correct the entire time. This thing has gone rotten.
0 replies
madnessofcrowds Oct 23, 1:50 PM
$DNA 50K block at 9.59
0 replies
Farorm Oct 23, 1:40 PM
$DNA fucking garbage company 💩
0 replies
madnessofcrowds Oct 22, 1:48 PM
$DNA bought 9.57
0 replies
madnessofcrowds Oct 22, 1:46 PM
$DNA bought 9.69
0 replies
madnessofcrowds Oct 21, 3:01 PM
$DNA bought 9.83
1 replies